EverSource Wealth Advisors LLC Raises Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

EverSource Wealth Advisors LLC boosted its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 96.8% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 620 shares of the specialty pharmaceutical company’s stock after purchasing an additional 305 shares during the period. EverSource Wealth Advisors LLC’s holdings in Jazz Pharmaceuticals were worth $76,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the company. CIBC Asset Management Inc increased its position in Jazz Pharmaceuticals by 5.2% in the fourth quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company’s stock worth $243,000 after buying an additional 97 shares during the last quarter. UMB Bank n.a. increased its position in Jazz Pharmaceuticals by 70.9% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after buying an additional 129 shares during the last quarter. Jones Financial Companies Lllp increased its position in Jazz Pharmaceuticals by 75.1% in the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock worth $37,000 after buying an additional 130 shares during the last quarter. Waterfront Wealth Inc. increased its position in Jazz Pharmaceuticals by 1.4% in the fourth quarter. Waterfront Wealth Inc. now owns 9,675 shares of the specialty pharmaceutical company’s stock worth $1,191,000 after buying an additional 137 shares during the last quarter. Finally, Ellsworth Advisors LLC increased its position in Jazz Pharmaceuticals by 0.4% in the fourth quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company’s stock worth $4,675,000 after buying an additional 149 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Price Performance

NASDAQ:JAZZ opened at $139.51 on Wednesday. The firm has a market capitalization of $8.47 billion, a price-to-earnings ratio of 19.65, a P/E/G ratio of 1.04 and a beta of 0.44. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $148.06. The stock has a fifty day moving average of $130.22 and a 200 day moving average of $121.18. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CMO Robert Iannone sold 7,080 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $138.60, for a total transaction of $981,288.00. Following the completion of the sale, the chief marketing officer now owns 82,024 shares of the company’s stock, valued at $11,368,526.40. The trade was a 7.95 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total value of $185,145.00. Following the sale, the chief executive officer now directly owns 425,525 shares of the company’s stock, valued at approximately $52,522,550.75. This trade represents a 0.35 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,736 shares of company stock valued at $4,022,825. Company insiders own 4.20% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on JAZZ shares. JPMorgan Chase & Co. raised their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Morgan Stanley reissued an “overweight” rating and issued a $183.00 target price (up from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. Truist Financial raised their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a report on Thursday, March 6th. Cantor Fitzgerald lowered Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and raised their price target for the stock from $140.00 to $150.00 in a report on Wednesday, February 26th. Finally, UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price target for the stock from $145.00 to $179.00 in a report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $187.71.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.